YMTX earnings

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash transaction Kineta, Inc., a private immuno-oncology company, to merge with Yumanity in an all-stock transaction that will advance Kineta's potential best-in-class VISTA blocking immunotherapy The combined company expects to close a PIPE financing in connection with the proposed merger Yumanity and Kineta to host webcast today at 8:30 a.m. EDT BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity") (NASDAQ:YMTX), a clinical-stage biopharmaceutic

YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson's disease YTX-7739 found to be generally well tolerated, demonstrating favorable pharmacokinetic/pharmacodynamic (PK/PD) profiles and a safety profile with no serious adverse events Conference call scheduled for 8:30 a.m. EST, Wednesday, November 10 BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease. The Company today reported that its lead product candidate, YTX-7739, in development for